Get the Stockscreener App
8.87
0.34%
-0.03
After Hours:
8.56
-0.31
-3.49%
Amicus Therapeutics Inc stock is traded at $8.87, with a volume of 3.79M.
It is down -0.34% in the last 24 hours and up +8.70% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$8.90
Open:
$8.88
24h Volume:
3.79M
Relative Volume:
0.78
Market Cap:
$2.73B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-72.41
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
-1.77%
1M Performance:
+8.70%
6M Performance:
+45.65%
1Y Performance:
-19.22%
1-Day Range:
$8.69
$8.98
1-Week Range:
$8.62
$9.64
52-Week Range:
$5.51
$11.36
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
8.87 | 2.75B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus targets $1B combined sales by 2028 as Galafold and Pompe therapies drive record growth - MSN
Does Amicus Therapeutics Inc. stock trade at a discount to peersTrade Entry Report & Weekly Chart Analysis and Guides - newser.com
How to manage a losing position in Amicus Therapeutics Inc.Day Trade & Weekly Return Optimization Plans - newser.com
Is Amicus Therapeutics Inc. (AM6) stock nearing a technical breakoutWatch List & Accurate Technical Buy Alerts - newser.com
How Amicus Therapeutics Inc. (AM6) stock moves in volatile trading sessionsWeekly Stock Analysis & Verified Chart Pattern Signals - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
JPMorgan Chase & Co. Increases Amicus Therapeutics (NASDAQ:FOLD) Price Target to $19.00 - MarketBeat
Is Amicus Therapeutics Inc. trending in predictive chart models2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryMarket Sentiment Review & Free Safe Capital Growth Stock Tips - newser.com
Is Amicus Therapeutics Inc. (AM6) stock undervalued at current priceOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Results: Amicus Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Understanding Amicus Therapeutics Inc.’s price movement2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Institutional scanner results for Amicus Therapeutics Inc.Gold Moves & High Yield Equity Trading Tips - newser.com
Is Amicus Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Will Amicus Therapeutics Inc. (AM6) stock benefit from mergers2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
JP Morgan Raises Price Target for Amicus Therapeutics (FOLD) to $19 | FOLD Stock News - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,643 Shares of Stock - MarketBeat
The Goldman Sachs Group Increases Amicus Therapeutics (NASDAQ:FOLD) Price Target to $11.00 - MarketBeat
Why Amicus Therapeutics Inc. stock is a must watch in 2025July 2025 PostEarnings & Technical Confirmation Alerts - newser.com
Is Amicus Therapeutics Inc. stock near bottom after declineWeekly Stock Summary & AI Powered Market Entry Ideas - newser.com
What earnings revisions data tells us about Amicus Therapeutics Inc.Forecast Cut & Smart Money Movement Alerts - newser.com
What is the fair value of Amicus Therapeutics Inc. stock nowQuarterly Portfolio Report & Risk Adjusted Buy/Sell Alerts - fcp.pa.gov.br
Is Amicus Therapeutics Inc. (AM6) stock trading at attractive multiplesWeekly Trend Recap & Real-Time Buy Signal Alerts - newser.com
Why Amicus Therapeutics Inc. stock attracts high net worth investorsRecession Risk & Fast Exit Strategy with Risk Control - fcp.pa.gov.br
Amicus Therapeutics Reports Strong Q3 Earnings Growth - The Globe and Mail
Using data models to predict Amicus Therapeutics Inc. stock movementPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com
Using RSI to spot recovery in Amicus Therapeutics Inc.July 2025 Drop Watch & Daily Profit Focused Stock Screening - newser.com
How Amicus Therapeutics Inc. stock performs after earningsDay Trade & Daily Entry Point Trade Alerts - fcp.pa.gov.br
Amicus Therapeutics (FOLD): Profitable Growth Forecasts Challenge Market’s Discounted Valuation - Yahoo Finance
Amicus Therapeutics Inc. stock chart pattern explainedEarnings Trend Report & Daily Technical Forecast Reports - newser.com
Can Amicus Therapeutics Inc. stock weather global recessionTrade Performance Summary & Weekly Hot Stock Watchlists - fcp.pa.gov.br
Insider Sell: David Clark Sells Shares of Amicus Therapeutics Inc (FOLD) - GuruFocus
Key resistance and support levels for Amicus Therapeutics Inc.Market Movement Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 7.8%Here's What Happened - MarketBeat
The Bull Case For Amicus Therapeutics (FOLD) Could Change Following First GAAP Profit and 17% Revenue Jump - Yahoo Finance
FOLD: Goldman Sachs Raises Price Target but Maintains Neutral Ra - GuruFocus
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues - sharewise.com
Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics - sharewise.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2025 Earnings Call Transcript - Insider Monkey
Visual trend scoring systems applied to Amicus Therapeutics Inc.CEO Change & Daily Stock Trend Reports - newser.com
Amicus Therapeutics Revenue Jump And Profit Turn Wall Street’s Head - Finimize
Amicus Therapeutics: Q3 Earnings Snapshot - CT Insider
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates - The Globe and Mail
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):